jueves, 19 de diciembre de 2024

T-DXd Shows Consistent Benefit Across Endocrine-Resistant HR+/HER2-Low Breast Cancer Subgroups Christos Evangelou, MSc, PhD December 19, 2024

https://www.medscape.com/viewarticle/t-dxd-shows-consistent-benefit-across-endocrine-resistant-hr-2024a1000ojy

No hay comentarios:

Publicar un comentario